OncoMatch/Clinical Trials/NCT03351842
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Is NCT03351842 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies cis Platinum/Carboplatin, Pemetrexed Disodium for chemotherapy, adjuvant.
Treatment: cis Platinum/Carboplatin, Pemetrexed Disodium — Randomized phase II trial aims to compare surgery with or without adjuvant chemotherapy in treating patients who are pathologically diagnosed as stage I lung adenocarcinoma with micropapillary component no less than 20%.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage I
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: chemotherapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
granulocytes >= 1,800/ul; platelets >= 100,000/ul
Liver function
bilirubin < 1.5 mg/dl; sgot (ast) < 2.0 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03351842 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage I is required.
Is there an age limit?
Yes. Patients must be 70 years or younger and at least 19 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages